C09988776 / invoice 10000
Species:CANINE
Breed:Poodle - Toy
Age (years):9
Diagnosis or signs:acth stim test
Consult notes
Animal clinical history (3 most recent)
2026-03-05T00:00:00Z 10:20 AM
Reason: Admit for ACTH stim test History: Trilostane 20mg/ml 0.6ml given this morning @ 6am (also gets 0.6mls in the pm) All OK - perhaps slightly less urination. Plan: Aim to pick her up by 11.45 am please. ACTH stim testProtocol - ideally fasted dog (If on trilostane - Perform the test 4-6 hours after administration of trilostane)1. Collect blood - plain tube, t=02. Inject 0.2ml synacthen IV RF @ 10.35am 3. Collect blood in plain tube (red top) at EXACTLY 1 hr after step 2, label t=1To run cortisol test;Need serumAssessment - Interpretation;* diagnosising cushings - resting cortsiol, t=0 should be normal or high (2-6ug/dl = 55-165nmol/L), t=1 should be much higher (18-22ug/dl - equivocal; > 22ug/dl = >607nmol/L => failure to suppress * if assessing effectivness of treatment => want resting and post acth stim cortisol to be <75nmol charges reflect inclusion of rt consult fee For Monitoring: Key pearls to put into practice:Trilostane therapy that starts with 0.5 to 1 mg/kg PO every 12 hours and gradually increases in dose is recommended for treatment of pituitary-dependent hyperadrenocorticism in dogs to minimize signs of hypoadrenocorticism.Periodic (ie, every 4-6 weeks) ACTH stimulation testing is recommended to monitor trilostane therapy. cpACTH >7 micrograms/dL, particularly when noted concurrently with unresolved clinical signs, indicates a dose increase is warranted. Dose escalation is common, possibly due in part to adrenal hyperplasia during therapy.Pet owners should be informed that cpACTH =27 micrograms/dL at the time of diagnosis indicates the trilostane dose will likely need to be gradually increased to achieve disease control. As basal (ie, pre-ACTH) cortisol had no predictive value in this study, basal cortisol measurement may be eliminated as a cost-savings measure, especially in patients without signs of hypoadrenocorticism.Most studies have evaluated dosage and efficacy of commercially available trilostane. Greater variability should be expected from compounded trilostane. Vital Signs
Previous claim history (19)
| Date | Claim # | Diagnosis |
|---|---|---|
| 2026-01-19 | C09799276 | HYPERADRENOCORTICISM ("CUSHING'S") |
| 2026-01-16 | C09766539 | HYPERADRENOCORTICISM ("CUSHING'S") |
| 2023-12-22 | C6714201 | SCOOTING |
| 2023-11-30 | C6593907 | GASTROINTESTINAL PROBLEMS |
| 2023-11-24 | C6754146 | PRESCRIPTION DIETS |
| 2023-11-13 | C6519903 | DIARROHEA |
| 2023-11-13 | C6533115 | GASTROINTESTINAL PROBLEMS |
| 2023-11-03 | C6488928 | DIARROHEA |
| 2023-10-27 | C6754146 | FLEA/TICK/WORM CONTROL |
| 2023-07-15 | C6111140 | VACCINATIONS OR HEALTH CHECKS |
| 2023-07-15 | C6111140 | ALTERNATIVE THERAPIES |
| 2023-05-06 | C5865004 | DIARRHOEA - PRESUMED SELF-LIMITING |
| 2023-02-10 | C5584098 | DENTAL (TOOTH) DISORDER |
| 2022-11-04 | C5333488 | PATELLA LUXATION |
| 2022-07-02 | C4887192 | VACCINE REACTION |
| 2022-07-01 | C4887183 | Grooming |
| 2022-07-01 | C4887183 | VACCINATIONS OR HEALTH CHECKS |
| 2022-07-01 | C4887183 | FLEA/TICK/WORM CONTROL |
| 2022-04-14 | C4663461 | GASTROINTESTINAL PROBLEMS |
Line items(lines with upstream diagnosis are skipped by the model)
| Line | tstarc | Amount | Date | Upstream diagnosis |
|---|---|---|---|---|
| 10000 | tstarc_hospitalisation | 125.01 | 2026-03-05 | — |
| 20000 | tstarc_diagnostic_test_-_acth_stimulation_test | 311.20 | 2026-03-05 | — |
| 30000 | tstarc_consultation-revisit | 110.00 | 2026-03-05 | — |
| 40000 | tstarc_synacthen | 150.29 | 2026-03-05 | — |
UPM+
- DG02293HYPERADRENOCORTICISM ("CUSHING'S")DSTP_hyperadrenocorticism_(cushing's_disease)
Variant (sleepy_king)
HYPERADRENOCORTICISM ("CUSHING's")
DSTP_hyperadrenocorticism_(cushing's_disease)
Conf: 0.990
Threshold: 0.18
Above: ✓
Correct?